Ultragenyx Pharmaceutical (BSP:R2AR34) Cyclically Adjusted FCF per Share: R$-3.54 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:R2AR34 Ultragenyx Pharmaceutical Inc BSP:R2AR34
43 GF Score
Price R$12.87
GF Value R$23.25
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share?

Ultragenyx Pharmaceutical BSP:R2AR34 +2.63% 43 Cyclically Adjusted FCF per Share is R$-3.54 as of Jun. 2026. GuruFocus rates BSP:R2AR34 with a GF Score™ of 43/100 and a GF Value™ of R$23.25 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Ultragenyx Pharmaceutical's adjusted free cash flow per share for the three months ended in Jun. 2026 was R$-4.928. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$-3.54 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -8.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Ultragenyx Pharmaceutical was -8.40% per year. The lowest was -8.40% per year. And the median was -8.40% per year.

As of today (2026-08-10), Ultragenyx Pharmaceutical's current stock price is R$12.87. Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was R$-3.54. Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is .


Ultragenyx Pharmaceutical  (BSP:R2AR34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Related Terms


Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ultragenyx Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -3.54

BSP:R2AR34 vs ATAI, QURE, KOD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.


BSP:R2AR34
43GF Score
Ultragenyx Pharmaceutical Inc BSP:R2AR34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ultragenyx Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-4.928/333.9520*333.9520
=-4.928

Current CPI (Jun. 2026) = 333.9520.

Ultragenyx Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -2.611 241.428 -3.612
201612 -3.975 241.432 -5.498
201703 -4.611 243.801 -6.316
201706 -3.829 244.955 -5.220
201709 -4.648 246.819 -6.289
201712 -6.318 246.524 -8.559
201803 -6.010 249.554 -8.043
201806 -5.863 251.989 -7.770
201809 -5.731 252.439 -7.582
201812 -4.365 251.233 -5.802
201903 -7.134 254.202 -9.372
201906 -6.321 256.143 -8.241
201909 -6.677 256.759 -8.684
201912 -5.930 256.974 -7.706
202003 -9.204 258.115 -11.908
202006 7.066 257.797 9.153
202009 -5.850 260.280 -7.506
202012 -6.712 260.474 -8.605
202103 -14.760 264.877 -18.609
202106 -6.354 271.696 -7.810
202109 -6.238 274.310 -7.594
202112 -5.804 278.802 -6.952
202203 -12.864 287.504 -14.942
202206 -7.809 296.311 -8.801
202209 -9.086 296.808 -10.223
202212 -8.771 296.797 -9.869
202303 -13.464 301.836 -14.897
202306 -9.078 305.109 -9.936
202309 -8.378 307.789 -9.090
202312 -5.196 306.746 -5.657
202403 -12.049 312.332 -12.883
202406 -5.068 314.175 -5.387
202409 -3.979 315.301 -4.214
202412 -5.106 315.605 -5.403
202503 -10.882 319.799 -11.364
202506 -6.306 322.561 -6.529
202509 -4.958 324.800 -5.098
202512 -5.506 324.054 -5.674
202603 -10.553 330.213 -10.672
202606 -4.928 333.952 -4.928

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$-3.54 mean?
Ultragenyx Pharmaceutical (BSP:R2AR34) has a Cyclically Adjusted FCF per Share of R$-3.54 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ultragenyx Pharmaceutical and its competitors.
Is Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share too high?
Ultragenyx Pharmaceutical's current Cyclically Adjusted FCF per Share is R$-3.54. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share compare to ATAI and QURE?
Ultragenyx Pharmaceutical's Cyclically Adjusted FCF per Share of R$-3.54 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Ultragenyx Pharmaceutical and its competitors. Ultragenyx Pharmaceutical's current Cyclically Adjusted FCF per Share is R$-3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Ultragenyx Pharmaceutical (BSP:R2AR34) is currently considered Possible Value Trap. The stock's GF Value™ is R$23.25, compared to a current price of R$12.87 — trading 44.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is R$-3.54. Ultragenyx Pharmaceutical's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (BSP:R2AR34), the current Cyclically Adjusted FCF per Share is R$-3.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (BSP:R2AR34) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of R$12.87 is trading 44.6% below its estimated GF Value™ of R$23.25. GuruFocus considers Ultragenyx Pharmaceutical to be Possible Value Trap.

Key valuation signals for BSP:R2AR34:

  • Cyclically Adjusted FCF per Share: R$-3.54
  • GF Value™: R$23.25 vs. price of R$12.87 (44.6% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the BSP:R2AR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ultragenyx Pharmaceutical Business Description

Other Exchanges RARE:USA0LIF:UKUP0:Germany
Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
43GF Score

Get the complete analysis for BSP:R2AR34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$12.87
Price
R$23.25
GF Value